Travere Therapeutics Inc- 詳細介紹、公司背景、業務範圍、財務數據以及市場表現

關於 Travere Therapeutics Inc 公司

Travere Therapeutics, Inc. 是一家生物製藥公司。該公司專注於爲患有罕見腎臟和代謝疾病的患者識別、開發和提供改變生活的療法。其產品 FILSPARI (sparsentan) 適用於降低患有原發性 IgAN 且有快速疾病進展風險的成人患者的蛋白尿。Sparsentan 還處於局竈節段性腎小球硬化症 (FSGS) 的後期開發階段。該公司的 Pegtibatinase 是一種新型的試驗性人類酶替代候選藥物，正在評估用於治療經典同型胱氨酸尿症 (HCU)，這是一種罕見的代謝性疾病。其商業產品 Thiola 和 Thiola EC 用於治療胱氨酸尿症，這是一種罕見的遺傳性胱氨酸轉運障礙，會導致尿液中胱氨酸水平高和複發性腎結石的形成。該公司還致力於識別 Alagille 綜合徵 (ALGS) 的潛在小分子療法。

Travere Therapeutics Inc簡介



公司代碼TVTX

公司名稱Travere Therapeutics Inc

上市日期Jul 23, 2003

CEODr. Eric M. Dube, Ph.D.

員工數量385

證券類型Ordinary Share

年結日Jul 23

公司地址3611 Valley Centre Dr

城市SAN DIEGO

上市交易所NASDAQ Global Market Consolidated

國家United States of America

郵編92130

電話18889697879

網址https://travere.com/

公司代碼TVTX

上市日期Jul 23, 2003

CEODr. Eric M. Dube, Ph.D.

Travere Therapeutics Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. Eric M. Dube, Ph.D.

President, Chief Executive Officer, Director

129.71K

--

Mr. Jeffrey A. Meckler

Independent Director

81.00K

+8.72%

Mr. Peter Heerma

Chief Commercial Officer

65.16K

-1.63%

Mr. Gary A. Lyons

Independent Chairman of the Board

51.00K

+14.61%

Mr. Timothy P. (Tim) Coughlin, CPA

Independent Director

49.00K

--

Dr. William E Rote, Ph.D.

Chief Research Officer

47.41K

+3.77%

Ms. Elizabeth E. Reed

Chief Legal Officer, General Counsel and Corporate Secretary

39.89K

--

Dr. Roy D. Baynes, M.D., Ph.D.

Independent Director

31.00K

+26.53%

Mr. John A. Orwin

Independent Director

28.88K

+29.05%

Mr. Ron R. Squarer

Independent Director

28.88K

+29.05%

名稱

名稱/職務

職務

持股

持股變動

Dr. Eric M. Dube, Ph.D.

President, Chief Executive Officer, Director

129.71K

--

Mr. Jeffrey A. Meckler

Independent Director

81.00K

+8.72%

Mr. Peter Heerma

Chief Commercial Officer

65.16K

-1.63%

Mr. Gary A. Lyons

Independent Chairman of the Board

51.00K

+14.61%

Mr. Timothy P. (Tim) Coughlin, CPA

Independent Director

49.00K

--

Dr. William E Rote, Ph.D.

Chief Research Officer

47.41K

+3.77%

收入明細

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

業務USD

名稱

營收

佔比

FILSPARI

71.89M

0.00%

Tiopronin Products

22.95M

0.00%

暫無數據

業務

地區

業務USD

名稱

營收

佔比

FILSPARI

71.89M

0.00%

Tiopronin Products

22.95M

0.00%

股東統計

更新時間: 10月30日週四

持股股東

股東類型

持股股東

佔比

Janus Henderson Investors

12.67%

Armistice Capital LLC

9.92%

BlackRock Institutional Trust Company, N.A.

7.48%

The Vanguard Group, Inc.

7.37%

Macquarie Investment Management

5.70%

其他

56.86%

持股股東

佔比

Janus Henderson Investors

12.67%

Armistice Capital LLC

9.92%

BlackRock Institutional Trust Company, N.A.

7.48%

The Vanguard Group, Inc.

7.37%

Macquarie Investment Management

5.70%

其他

56.86%

股東類型

持股股東

佔比

Investment Advisor

41.64%

Investment Advisor/Hedge Fund

35.12%

Hedge Fund

33.52%

Private Equity

6.14%

Research Firm

4.65%

Venture Capital

1.29%

Individual Investor

0.82%

Bank and Trust

0.35%

Pension Fund

0.28%

機構持股



更新時間: 10月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

458

107.07M

119.68%

-12.73M

2025Q2

470

104.47M

117.23%

-11.51M

2025Q1

484

101.83M

114.67%

-16.19M

2024Q4

461

96.91M

109.26%

-9.67M

2024Q3

448

85.09M

109.18%

-32.25M

2024Q2

444

90.35M

118.12%

-28.07M

2024Q1

437

90.02M

118.29%

-22.39M

2023Q4

428

87.89M

116.97%

-15.26M

2023Q3

417

84.96M

113.19%

-18.05M

2023Q2

411

85.35M

113.93%

-14.35M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Janus Henderson Investors

11.34M

12.72%

+1.80M

+18.85%

Jul 31, 2025

Armistice Capital LLC

8.88M

9.96%

+4.00K

+0.05%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

6.69M

7.51%

-25.65K

-0.38%

Jun 30, 2025

The Vanguard Group, Inc.

5.98M

6.7%

+980.26K

+19.62%

Jun 30, 2025

Macquarie Investment Management

5.10M

5.72%

+300.17K

+6.26%

Jun 30, 2025

State Street Investment Management (US)

3.48M

3.91%

-163.54K

-4.48%

Jun 30, 2025

Emerald Advisers LLC

3.23M

3.63%

+33.73K

+1.05%

Jun 30, 2025

Adage Capital Management, L.P.

2.78M

3.12%

+599.10K

+27.42%

Jun 30, 2025

Renaissance Technologies LLC

2.50M

2.8%

-207.70K

-7.68%

Jun 30, 2025

持股ETF



更新時間: 11月6日週四

機構名稱

佔比

Invesco Pharmaceuticals ETF

3.66%

Virtus LifeSci Biotech Products ETF

2.66%

Innovator IBD 50 Fund ETF

2.64%

Invesco Dorsey Wright Healthcare Momentum ETF

2.18%

ALPS Medical Breakthroughs ETF

1.39%

Franklin Genomic Advancements ETF

0.8%

SPDR S&P Biotech ETF

0.55%

First Trust Multi-Manager Small Cap Opportunities ETF

0.48%

First Trust Small Cap Growth AlphaDEX Fund

0.36%

Direxion Daily S&P Biotech Bull 3X Shares

0.29%

Invesco Pharmaceuticals ETF

佔比3.66%

Virtus LifeSci Biotech Products ETF

佔比2.66%

Innovator IBD 50 Fund ETF

佔比2.64%

Invesco Dorsey Wright Healthcare Momentum ETF

佔比2.18%

ALPS Medical Breakthroughs ETF

佔比1.39%

Franklin Genomic Advancements ETF

佔比0.8%

SPDR S&P Biotech ETF

佔比0.55%

First Trust Multi-Manager Small Cap Opportunities ETF

佔比0.48%

First Trust Small Cap Growth AlphaDEX Fund

佔比0.36%

Direxion Daily S&P Biotech Bull 3X Shares

佔比0.29%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據